Currently, the most widely used methods for detecting EGFR mutations in NSCLC are gene sequencing, fluorescent in situ hybridazation and immunohistochemical assays, however, they present important limitations for EGFR-TKIs therapy. Here, EGFR is linked to non-small cell lung carcinoma.